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a  b  s  t  r  a  c  t
This  study  uses  a dynamic  inﬂuenza  transmission  model  to directly  compare  the cost-effectiveness  of
various  policies  of  annual  paediatric  inﬂuenza  vaccination  in  England  and  Wales,  varying  the target  age
range  and  level  of  coverage.  The  model  accounts  for  both  the  protection  of  those  immunised  and  the
indirect  protection  of  the  rest  of  the  population  via  herd  immunity.  The  impact  of augmenting  current
practice  with  a policy  to  vaccinate  pre-school  age  children,  on  their  own  or with  school  age children,
was  assessed  in terms  of  quality  adjusted  life  years  and  health  service  costs.  Vaccinating  2–18  year olds
was estimated  to be  the  most  cost-effective  policy  in  an  incremental  cost-effectiveness  analysis,  at  an
assumed  annual  vaccine  uptake  rate  of 50%. The  mean  incremental  cost-effectiveness  ratios  for  this
policy  was  estimated  at £251/QALY  relative  to current  practice.  Paediatric  vaccination  would  appear  toransmission model
athematical model
ost-effectiveness
aediatric
accination
ngland
be a highly  cost-effective  intervention  that  directly  protects  those  targeted  for vaccination,  with  indirect
protection  extending  to both  the very  young  and  the  elderly.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.ales
. Introduction
Inﬂuenza infections lead to a signiﬁcant health burden in
ngland and Wales, resulting annually in approximately one
illion general practice (primary care) consultations, 25,000 hospi-
alisations and 20,000 deaths [1].  The most severe outcomes occur
n those with underlying disease and in the very young and in the
lderly.
Since the late 1960s, inﬂuenza immunisation with an inactiv-
ted vaccine has been recommended for those people at greatest
isk of serious complications from inﬂuenza, such as those with
hronic heart disease, or living in long-stay residential accommo-
ations where the virus may  spread easily.
In 1998, the vaccination programme in the UK was extended
o include all those aged 75 years and over. In 2000, this was  fur-
her extended to those aged 65 years and over and to front line
mployees in the National Health Service (NHS) and in social care.The Joint Committee on Vaccination and Immunisation (JCVI)
eeps the inﬂuenza immunisation programme under regular
eview. This includes evaluating new cost-effectiveness studies as
∗ Corresponding author. Tel.: +44 1865 324930; fax: +44 1865 324931.
E-mail address: richard.pitman@oxfordoutcomes.com (R.J. Pitman).
264-410X     ©  2012 Elsevier Ltd. 
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Open access under CC BY-NC-ND license.they are published. Additional risk groups have been added to the
programme following careful consideration of available medical
and scientiﬁc evidence.
There have been a number of studies, both in the UK [2]
and elsewhere [3,4], examining the cost-effectiveness of introduc-
ing a policy of paediatric inﬂuenza vaccination. These have been
reviewed previously [5] and, while they have generally found pae-
diatric inﬂuenza vaccination to be either cost-effective or cost
saving, they have all utilised a static modelling approach, that can-
not account for the indirect protection (herd immunity) potentially
afforded by vaccination.
In order to be adopted, a new intervention strategy must com-
pete across all available therapeutic areas for a limited health
service budget. If policy makers are to reach an appropriate deci-
sion, the competing strategies must all be evaluated accurately.
An effective vaccination strategy may  result in the indirect protec-
tion of unvaccinated sectors of a community, signiﬁcantly affecting
the strategy’s estimated cost-effectiveness. To accurately evalu-
ate these strategies, economic analyses must utilise a modelling
approach that captures the dynamics of pathogen transmission in
the whole community, and accounts for indirect protection (herd
immunity).
The objective of this analysis was  to use a previously pub-
lished dynamic inﬂuenza transmission model [6] to assess the
928 R.J. Pitman et al. / Vaccine 
Fig. 1. The age stratiﬁed dynamic transmission model simulates the ﬂow of indi-
viduals between population compartments deﬁned by inﬂuenza infection and
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daccination status: Susceptible, Exposed (latently infected), Infectious, Recovered
nd Vaccinated. Infected individuals may  or may  not be symptomatic. a is the age
ependent rate of vaccination. See Table A1 for a list of the remaining parameters.
ost-effectiveness of introducing a policy of annual paediatric
nﬂuenza vaccination in England and Wales, accounting for both
he protection of those immunised and the indirect protection of
he rest of the population via herd immunity.
. Methods
.1. Overview
This cost-effectiveness analysis utilised a dynamic transmission
odel (Fig. 1) to estimate the impact of paediatric vaccination
n the 200 year cumulative number of inﬂuenza related clini-
al outcomes (general practice consultations, hospitalisations and
eaths). Details of this model have been published previously [6].
hese outcomes were translated into beneﬁts, expressed in terms
f quality adjusted life years (QALYs), and costs assessed from the
erspective of the NHS.
This framework was used to assess the cost-effectiveness of the
ollowing policy options for paediatric vaccination:
Choice of vaccine:
◦ Live attenuated inﬂuenza vaccine (LAIV).
◦  Trivalent inactivated inﬂuenza vaccine (TIV).
Choice of target age group for paediatric vaccination:
◦ Pre-school (2–4 years of age).
◦ Pre and primary school children (2–10 years of age).
◦ All children (2–18 years of age).
It was assumed that these options would be implemented in
ddition to the current practice of vaccinating those at increased
isk of inﬂuenza associated morbidity, including everyone of 65
ears of age and over, with TIV.
.2. Model design
Brieﬂy, the transmission model (Fig. 1) simulated the population
ide transmission dynamics of inﬂuenza A and B infection, irre-
pective of whether or not they were symptomatic, with the model
peciﬁcation and parameter values remaining the same as previ-
usly published [6] (Table A1). All economic analysis was carried
ut using Microsoft Excel (2010).A set of risk functions translated incident infections, simulated
sing the above transmission model, into General Practice (GP) con-
ultations, hospitalisations and deaths (Fig. 2). These risk functions
ere derived from model simulations and previously published
ata on the burden of inﬂuenza in England and Wales [1].31 (2013) 927– 942
2.3. Data sources
The primary data analysis in this study was based on the follow-
ing sources:
• General Practice Research Database (GPRD), 2000–2009.
• Personal and Social Services Research Unit (PSSRU), University of
Kent, annual report, 2008.
• Hospital Episode Statistics (HES), 2005–2006.
• National Health Service (NHS) reference costs, 2008.
The GPRD was used to estimate staff time associated with vac-
cine administration and the medical management of patients with
inﬂuenza-like-illness (ILI). Staff time was costed using data from
the PSSRU annual report [7].  In addition, the cost of ILI treatment
in a primary care setting was  estimated, under the assumption
that this arose primarily from the cost of broad spectrum antibi-
otic use, associated with prophylaxis or treatment of ILI-associated
complications. Hospital Episode Statistics provided an estimate of
the mean duration of hospital stay for patients with laboratory
conﬁrmed inﬂuenza, the cost of which was  estimated using NHS
reference costs.
2.3.1. General Practice Research Database
The GPRD [8] is a computerised database of anonymised longitu-
dinal medical records from primary care, linked to other healthcare
data. The GPRD was  selected for use in this study due to the size of
its population base, with data drawn from over 500 primary care
practices throughout the UK, it contains information on approxi-
mately 9.8 million patients (∼7% of the population) covering more
than 57 million person years. The GPRD uses the Read/OXMIS sys-
tems of diagnostic coding [9].  Records for consultation where an
inﬂuenza-like-illness (ILI) was recorded (see appendix for the full
code list) between 2000 and 2009 were extracted.
2.3.2. Hospital Episode Statistics
Hospital Episode Statistics [10] (HES) is a data warehouse con-
taining individual patient records detailing all admissions to NHS
hospitals in England since 1989. It includes private patients treated
in NHS hospitals, patients who were resident outside of England
and care delivered by treatment centres (including those in the
independent sector) funded by the NHS. HES also contains details
of all NHS outpatient appointments in England.
Data were downloaded detailing the mean length of stay, by
age, derived from total reports of laboratory conﬁrmed inﬂuenza
(ICD10 code J10) for all strategic health authorities in 2005/06.
2.4. Costs
2.4.1. Vaccination
Vaccination was  assumed to take place within primary care and
to be administered by a physician, incurring the staff cost of a con-
sultation [7].  The price of the vaccine was  taken to be the mean list
price of the trivalent inactivated inﬂuenza vaccines (TIVs) listed in
the British National Formulary (BNF, release 57), without weight-
ing for frequency of use. Published values for the dispensing fee and
container allowance [11] were adopted and the on cost allowance
estimated at 10.5% of the basic cost of the vaccine. Price parity was
assumed between the live attenuated inﬂuenza vaccine (LAIV) and
the mean TIV cost, unless stated otherwise.
2.4.2. Primary care
The mean primary care related cost per inﬂuenza episode was
estimated by ﬁrst calculating the total number of ILI consultations
recorded in the GPRD between 2000 and 2009. All ILI consulta-
tions were stratiﬁed by patient identiﬁcation number and any that
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iig. 2. Overview of the modelling process. A dynamic transmission model simula
nfections into general practice consultations, hospitalisations and deaths. The imp
f  disease information informs a decision analytic model used to estimate the incre
ccurred within 30 days of each other were assumed to be part of
he same episode. This allowed the mean number of consultations
er episode to be estimated.
The cost of an ILI related GP consultation can be split into staff
alary costs and those arising from prescribed medications. The
PRD data record the duration of each consultation, stratiﬁed by
taff role (doctor, nurse, other) and consultation type (surgery visit,
ome visit, telephone consultation, administration, other). Com-
ining these data with salary costs [7] allowed the mean salary
ost of a consultation to be estimated.
Broad spectrum antibiotics are used to treat the common com-
lications of inﬂuenza in children and the wider population seen
ithin primary care. These complications include acute otitis
edia, pneumonia and sinusitis. A record of all broad spectrum
ntibiotics prescribed in primary care consultations during which
n inﬂuenza-like-illness was recorded was extracted from the
PRD.
The list price [12] of each broad spectrum antibiotic prescription
as used to calculate the total cost of prescribing across the popu-
ation. Dividing by the total number of consultations produced an
stimate of the mean prescription cost per consultation.
The mean prescription and staff cost of an ILI consultation were
ombined to give the mean overall cost of a consultation. Mul-
iplying by the number of consultations per episode yielded an
stimate of the mean primary care related cost of an inﬂuenza
pisode.
.4.3. Hospitalisations
The Hospital Episodes Statistics 2005/06 database provided an
stimate of the mean length of stay associated with an admission
ith a laboratory conﬁrmed inﬂuenza infection, stratiﬁed by age.
he daily cost was derived from NHS reference costs [13] using
he cost associated with lobar, atypical or viral pneumonia without
omplications.
Costs taken from previous years were inﬂated to 2008 values
GB£) using the Hospital and Community Services Pay and Prices
ndex [7].
.5. Outcomes.5.1. Clinical outcomes
A previously deﬁned set of risk functions [6] quantiﬁed the prob-
bility of an inﬂuenza infection resulting in a symptomatic case of
nﬂuenza, a GP consultation, hospitalisation or death.e incidence of inﬂuenza infection. A set of risk functions then translate incident
 quality of life and associated cost implications can then be estimated. This burden
l costs and QALYs associated with alternative intervention strategies.
2.5.2. QALYs
In a previous study [11], the mean reduction in an individual’s
quality of life resulting from clinically apparent inﬂuenza was  esti-
mated and summed over a 21 day period to arrive at an estimated
average loss of 0.02 QALYs per episode of inﬂuenza. Given the lack
of corresponding data for children, this value was applied to both
children and adults. The number of incident inﬂuenza cases (symp-
tomatic infections) was multiplied by the average QALY loss per
episode to arrive at the total QALY loss resulting from inﬂuenza dis-
ease. The number of incident inﬂuenza cases was also multiplied by
the age speciﬁc probability of death allowing the number of quality
adjusted years of life lost to be calculated and discounted, assum-
ing a mean life expectancy at birth of 84 years. This was added to
the QALY loss resulting from inﬂuenza disease to arrive at an esti-
mate of the total QALY loss. The difference in QALYs lost between
intervention options could then be calculated.
2.6. Analysis
2.6.1. Vaccination policy scenarios
Current practice in England and Wales involves vaccinating
everyone over the age of 64 years and anyone between 6 months
and 64 years of age in a deﬁned risk group [14] with TIV. This policy
was introduced in 2000.
The proportion of the population estimated to have been vac-
cinated under the current policy was based on data published by
the Health Protection Agency for England and Wales [14,15].  The
efﬁcacy of TIV has been estimated previously [16,17] (Table A2).
Paediatric vaccination policy scenarios were constructed exam-
ining three different target age ranges (2–4, 2–10 and 2–18 years of
age inclusive) and two different vaccine options (TIV or LAIV), used
in addition to current practice.
Both LAIV and TIV are approved in the EU for use in children.
LAIV is approved in eligible children 24 months to less than 18
years of age; TIV formulations are approved for varying age ranges,
with products approved for use in children as young as 6 months
of age.
Both vaccines have been demonstrated to be efﬁcacious in chil-
dren in multiple placebo-controlled studies [17–20].  Three large,
prospective, randomized studies conducted during two  different
Northern Hemisphere inﬂuenza seasons have compared the safety
and efﬁcacy of LAIV and TIV in children 6 months to 17 years
of age. In these studies, LAIV recipients had 35–53% fewer cases
of inﬂuenza illness caused by antigenically similar strains com-
pared with TIV recipients, with comparable safety among children
930 R.J. Pitman et al. / Vaccine 
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ssumes 50% coverage of 2–18 year old children with LAIV, in addition to current
ractice.
 years of age and older [21–23].  Overall, LAIV was associated with
ncreased rates of runny nose/nasal congestion, fever 37.8–38.9 ◦C,
nd decreased appetite [21–23],  while TIV was associated with
ncreased injection site reactions [22].
The efﬁcacy of LAIV in children from 2 to 18 years of age was
ssumed to be 80% [17,20]. That of TIV was assumed to be 60% in
hildren, 50% in the elderly and 75% in recipients aged 19–64 years
ld [16,17].
The base case assumed a paediatric coverage rate of 50% for both
AIV and TIV.
.6.2. Economic evaluation
Vaccination is a population wide intervention and the resulting
eneﬁts may  continue to accrue beyond the limit of any analytical
ime horizon. It is therefore necessary to use a sufﬁciently long time
orizon such that discounted costs and beneﬁts no longer change as
he time horizon is further extended [24]. This occurs in the current
odel at a horizon of 150–200 years (Fig. 3).
Cumulative costs and total QALYs lost were calculated over a
00 year period, from 2009 to 2208 and discounted at an annual
ate of 3.5% [25]. An incremental cost-effectiveness analysis was
ndertaken of the 200 year cumulative cost and sum of QALYs lost
ssociated with each paediatric vaccination policy. These costs and
ffects associated with the policy under consideration are often
eferred to as decision payoffs.
The decision concerning cost-effective service provision given
xisting information involves identifying the strategy associated
ith the best decision payoff given no additional information
26,27]. Within the evaluation of health technologies, decision pay-
ffs are expressed in terms of the net beneﬁt associated with
trategy (i) expressed in either health outcome () or monetary
erms () [27–31].
i = QALYi −
(
Costi ×
(
1

))
i = ( × QALYi) − Costi
here  is the cost-effectiveness threshold.
If the objective is to maximise health gain subject to a budget
onstraint, then the decision regarding service provision should be
ased on expected payoffs, measured in terms of expected (mean)
et beneﬁt [28,32–34].
An incremental cost-effectiveness ratio (ICER) was calculated,
tarting from a scenario of no vaccination and dropping vaccination
olicies that were dominated, either directly (higher cost and lower
eneﬁt) or via extended dominance (lower beneﬁt and higher ICER).
he remaining vaccination policies were then ranked in order of
scending beneﬁt (incremental QALYs).31 (2013) 927– 942
A probabilistic sensitivity analysis (PSA) was  used to account
for uncertainty in the economic and clinical input parameters in
the cost-effectiveness analysis (Table A3). Inﬂuenza transmission
parameters were not included for practical reasons.
The parameter values in a PSA are normally drawn from deﬁned
distributions, either independently, or guided by the known covari-
ance between parameters. This approach is problematic when
dealing with the transmission parameters of an infectious disease.
For many of the transmission parameters, their plausible values are
dependent on the current value of a number of other parameters,
in order, for example, to maintain consistency with the range of
possible values of the basic reproductive number.
From a practical perspective, for a PSA to accurately represent
the uncertainty in a set of parameters, their joint distribution must
be adequately sampled, which is not possible when dealing with a
very large number of parameters. A further practical point is that
any transmission model that takes more than a few seconds to run
would result in a PSA, requiring tens of thousands of runs, taking
an impractical length of time to complete.
Following the PSA of the clinical and economic parameters, the
probability of each of the paediatric vaccination policies being cost-
effective over a range of cost-effectiveness thresholds was plotted
as a set of cost-effectiveness acceptability curves (CEACs).
The policy with the greatest expected net beneﬁt, at any one
cost-effectiveness threshold, may  not correspond to the one with
the highest probability of being cost-effective. This may  arise as
a result of a policy having a positively skewed distribution of net
beneﬁt [34]. The probability of the optimum policy (the one with
the highest expected net beneﬁt) being cost-effective over a range
of cost-effectiveness thresholds was  calculated and plotted as a
cost-effectiveness acceptability frontier (CEAF).
In addition, the sensitivity of the selected policy’s ICER to a 10%
variation in key parameters (Table A4) was estimated in a univari-
ate sensitivity analysis and the vaccine price yielding an ICER equal
to £20,000 per QALY (the break even price) calculated. The value
of £20,000 per QALY is the lower range of the cost-effectiveness
threshold used by the National Institute for Health and Clinical
Excellence (NICE) [35].
A threshold cost analysis was  also conducted, in which 50% cov-
erage of 2–18 year old children with TIV was compared to a similar
coverage using LAIV. The price of LAIV was increased, from a point at
parity with TIV, until the net monetary beneﬁt (NMB) was  reduced
to zero, providing an estimate of the price premium that could be
supported by the higher efﬁcacy of LAIV. A cost per QALY of £20,000
was assumed in the NMB  calculation. This differs from the break
even price calculation in that the comparator for the break even
price is current practice, whereas in the price threshold analysis
50% coverage with LAIV in 2–18 year old children is compared to
similar paediatric vaccination using TIV.
The impact on the ICER, of adopting each of the following ‘what
if’ parameter options was  also estimated:
• Higher or lower basic reproductive number (R0, deﬁned as
the number of secondary infections produced by one primary
infection in a totally susceptible population). The transmission
coefﬁcient was  adjusted to give an R0 of 1.4 and 2.2 (base case
value of 1.8).
• Duration of immunity: the durations of protection to inﬂuenza A
and B were set to be equal at 2 years and 12 years (base case was
A: 6 years, B: 12 years).
• Seasonality: the seasonal variation in the ease of inﬂuenza trans-
mission was set to zero (base case was a sine wave with amplitude
equal to 1.43 times the mean).
• Population mixing: a unit WAIFW matrix was adopted to simulate
random (homogeneous) population mixing, while adjusting the
ccine 31 (2013) 927– 942 931
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Table 2
Mean estimated primary care cost of an ILI episode, broken down by age of patient
and  split into staff and prescribing costs.
Patient age
group (years)
Mean staff
cost
Mean prescribing
cost per episode
Mean total
cost
0–1 £87.20 £0.91 £88.11
2–4  £63.43 £1.11 £64.54
5–10  £53.35 £0.97 £54.32
11–18 £64.81 £1.06 £65.87
19–49 £83.76 £1.03 £84.78
50–64 £99.57 £1.15 £100.72
icy was highly cost-effective, with the use of LAIV being cost-saving
and dominating TIV use in this age group. Broadening the age range
of children vaccinated with LAIV to 2–10 years resulted in an ICER
of £506, with LAIV use dominating that of TIV. Further extendingR.J. Pitman et al. / Va
transmission coefﬁcient to maintain an R0 of 1.8 (base case set as
the POLYMOD study all contacts matrix [36].
LAIV efﬁcacy: the efﬁcacy of LAIV was set to 60%, equal to that of
TIV in children (base case LAIV efﬁcacy was 80%).
As the impact of a vaccination programme is in part dependent
n the level of vaccine uptake achieved in the population, a sce-
ario analysis was undertaken to examine the impact on the ICER,
elative to current practice, of varying vaccine uptake between 10%
nd 90%.
In order to investigate the contribution made by indirect pro-
ection, arising from herd immunity, in those not targeted for
accination, the cost-effectiveness acceptability frontier was  recal-
ulated using costs and QALYs derived exclusively from the age
roups targeted for paediatric vaccination.
In addition to these ‘what-if’ scenarios, a systematic extreme
alue analysis was carried out. The following parameters were var-
ed between high, medium (base-case), and low values:
Basic reproductive number, R0: 1.2, 1.8, 3.4.
Duration of natural disease immunity (protection to inﬂuenza
arising from infection and recovery):
◦  Inﬂuenza A: 3, 6, 7 years,
◦ Inﬂuenza B: 6, 12, 13 years.
Duration of vaccine-induced disease immunity:
◦ Inﬂuenza A: 5, 6, 7 years,
◦  Inﬂuenza B: 11, 12, 13 years.
Latent period: 1, 2, 7 days.
Infectious period: 1, 2, 7 days.
The dynamic transmission model was run for inﬂuenza A and
 and the ICER, relative to current treatment, calculated for all
5 combinations of these parameters. The transmission coefﬁcient
as recalculated each time in order to achieve the desired R0 for
he given duration of infectiousness and latency. Other parameters
ere maintained at baseline values. LAIV efﬁcacy was 80% and 50%
overage in 2–18 year olds was assumed.
. Results
.1. Estimation of costs
.1.1. Vaccination
The staff cost of administering the vaccine constituted approx-
mately 80% of the total cost of vaccination within primary care
Table 1). The price of the vaccine constituted 15% of the total cost
nd was estimated by averaging a total of 11 TIV list prices [37],
anging from £4.40 to £6.59, to arrive at a mean price of £5.81,
ithout weighting for frequency of use. The resulting estimated
ost of administering one dose of the TIV was £38.60. The price of
AIV was assumed to be the same as TIV.
able 1
onstituents of the cost of administering a single dose of TIV vaccine within primary
are [7,11,37].
Item Cost
Vaccine cost £5.81
Dispensing fee £1.14
Container allowance £0.03
On  cost allowance 10.5% basic cost of vaccine £0.61
GP  consultation cost £31.00
Total £38.6065+ £98.82 £1.19 £100.02
All  ages £78.70 £1.06 £79.77
3.1.2. Primary care
Data on 183 million ILI related general practice consultations
from between 2000 and 2009 were analysed. The mean cost of
a consultation with a physician was £21.07. The mean staff cost
incurred within primary care over an ILI episode was  estimated to
be £78.70, however there was  wide variation depending on the age
of the patient (Table 2). Children ages 5–10 years incurred the least
expense and those over 49 the greatest.
The mean prescription cost for broad spectrum antibiotics, dur-
ing an ILI related episode, was  £1.06 (Table 2). This varied between
£0.91 in the under ones and £1.19 in the over 65 years olds.
Combining the staff and prescribing costs resulted in a mean
estimated cost, in primary care, of an ILI episode that varied
between £54 in 5–10 year olds to £100 in patients over 50 years
old (Table 2).
3.1.3. Hospitalisation
The mean cost of an inﬂuenza related hospitalisation was esti-
mated to be between £1600 and £2000, except in the elderly for
whom it rises to over £5000 and is more variable (Table 3).
3.2. Cost-effectiveness
This analysis estimated that, in the absence of vaccination,
inﬂuenza related morbidity and mortality would result in the loss
of approximately 1.2 million QALYs per year, at an annual cost
in the region of £915 million. Each of the vaccination policies
considered had a substantial impact on the 200 year cumulative
loss of QALYs and associated costs (Table 4).
The current vaccination policy of vaccinating those individuals
that are at an increased risk of inﬂuenza associated morbidity,
including the elderly, was  estimated to be cost saving, relative to not
vaccinating at all. Adding pre-school vaccination to the current pol-Table 3
The mean length of stay [10] and associated cost [13] of an inﬂuenza related hospital
admission.
Age group Mean length of
stay (days)
National average
cost (£)
SE
0–11 mo 6 1606 449
12–23 mo  6 1606 449
24–59 mo  6 1606 449
5–10  yr 6 1606 449
11–18 yr 6 1634 457
19–49 yr 6 1662 465
50–64 yr 7 1983 555
65+  yr 19 5354 1497
All  Ages 8 2123 594
932 R.J. Pitman et al. / Vaccine 31 (2013) 927– 942
Table  4
Incremental cost-effectiveness analysis of implementing a programme of paediatric inﬂuenza vaccination in children aged 2–4, 2–10 or 2–18 years old, exclusively using
either  a live attenuated inﬂuenza vaccine (LAIV) or a trivalent inﬂuenza vaccine (TIV), in addition to current practice. An annual paediatric vaccine uptake rate of 50% is
assumed. Cumulative ﬁgures over 200 years.
Policy option QALYs lost (millions) Cost (millions) Incremental
QALYs (millions)
Incremental cost
(millions)
ICER
No vaccination −27.7 £27,468
Current policy −7.7 £18,304 20.0 −£9164 Cost saving
Current policy + TIV in 2–4 year olds −6.2 £18,496 1.6 £192 Dominated
Current policy + LAIV in 2–4 year olds −5.7 £18,122 2.0 −£182 Cost saving
Current policy + TIV in 2–10 year olds −3.9 £19,677 1.8 £1554 Dominated
Current policy + LAIV in 2–10 year olds −3.4 £19,275 2.3 £1152 £506
0,493
9,973
c
r
t
t
p
Q
3
3
m
p
c
v
t
o
t
t
3
w
p
u
c
F
oCurrent policy + TIV in 2–18 year olds −1.7 £2
Current policy + LAIV in 2–18 year olds −1.1 £1
overage to children aged 2–18 remained highly cost-effective and
esulted in a further gain in QALYs, with LAIV use again dominating
he use of TIV, with an ICER of £298 per QALY gained.
The incremental cost-effectiveness analysis suggests that, of
hose strategies considered, vaccinating 2–18 year olds with LAIV
rovides the greatest affordable beneﬁt with an estimated cost per
ALY gained (ICER) below £1000 at an assumed uptake rate of 50%.
.3. Sensitivity analysis
.3.1. Probabilistic sensitivity analysis
Given the existence of uncertainty in the model parameter esti-
ates, the cost-effectiveness acceptability curves evaluated the
robability of each policy being the most cost-effective at a range of
ost-effectiveness thresholds (Fig. 4). At thresholds above £1000,
accinating 2–18 year olds with LAIV was invariably the policy with
he highest probability of being cost-effective, as well as being the
ptimum policy in terms of expected net beneﬁt (Fig. 5). Reducing
he upper limit from 18 to 17 makes no qualitative difference to
his result.
.3.2. Univariate sensitivity analysis
The inﬂuence of vaccine uptake on the cost per QALY gainedas highly non-linear (Fig. 6). Increasing vaccine uptake to 50%
roduced a substantial reduction in lost QALYs. Higher rates of
ptake, beyond 50%, produced little additional gain at increasing
ost. The combined effect produced an ICER relative to current
ig. 4. Cost-effectiveness acceptability curves, over a range of cost-effectiveness threshold
ut  of those included in the analysis. An annual paediatric uptake rate of 50% is assumed, 1.7 £1218 Dominated
 2.3 £699 £298
practice that ranged from cost saving at 10% uptake to £951 at 90%
uptake (Table 5) and which increased almost linearly at a rate of
£1711/QALY for each percentage point increase in uptake, at uptake
rates above 40% (Fig. 7). This gradient declines with decreasing
coverage below 20%, becoming almost ﬂat below 10%.
By varying key parameters by 10% either side of their base value,
it was possible to demonstrate that changes in the basic reproduc-
tive number of the virus would be expected to have the greatest
impact on the ICER, relative to current treatment, of vaccinating
2–18 year olds at annual vaccination uptake rates of 50% and 80%
(Fig. A1). The duration of immunity to inﬂuenza B and the price of
the vaccine had the least inﬂuence. The vaccine price break even
point was  estimated to be approximately £559.
The price threshold analysis yielded a price of £46.63 for LAIV,
at which the net monetary beneﬁt of using LAIV over TIV (priced at
£5.81) for paediatric vaccination was  reduced to zero.
Varying the basic reproductive number over the range of plausi-
ble values (1.4–2.2) resulted in an ICER, for vaccinating 80% of 2–18
year olds, of between £550 and £2663 (Fig. A2). This reduced to
between £154 and £1352 at an uptake rate of 50%. Increasing the
duration of immunity to inﬂuenza A to 12 years, as assumed for B,
produced an ICER of £2601 at 80% uptake and £1319 at 50% uptake.
Decreasing the duration of immunity to A and B to 2 years resulted
in an ICER that was  cost saving at both 50% and 80% uptake. Remov-
ing the inﬂuence of seasonal forcing, heterogeneous mixing and the
efﬁcacy advantage of LAIV over TIV similarly failed to produce an
ICER that was not cost-effective.
s, estimating the probability of each vaccination policy being the most cost-effective
 exclusively using either LAIV or TIV in the age ranges 2–4, 2–10 or 2–18 years.
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herd immunity, may  make a signiﬁcant contribution to the cost-
effectiveness of paediatric inﬂuenza vaccination. There has been
F
wFig. 5. Cost-effectiveness acceptability frontier, indicating the probability of co
.3.3. Extreme value analysis
In the extreme value analysis there was a large variation in the
CERs calculated. For analysis the results were stratiﬁed by the R0
alue used (Fig. A3).
For the baseline R0 value of 1.8, depending on the durations
f immunity and the latent and infectious periods, the ICER varied
etween a cost-saving −£329 and a maximum of £1179. This range
as the smallest produced by the three R0 values.
With a low basic reproduction number of 1.2, the variation
as much wider and the LAIV option was never cost-saving, espe-
ially as the durations of immunity and infection increased. That
s, assuming fewer secondary cases and a slower time-frame, the
ffort of intensive vaccination was less cost-effective, resulting in a
orst-case ICER of £16,162 for the combination with all maximum
urations.
With a very high R0 of 3.4 there was slightly more variation in the
esultant ICERs than for the baseline value, reﬂecting the difﬁculty
n preventing QALY loss assuming a larger number of secondary
ases. The ICER ranged between −£265 (cost-saving) and £3079.
ig. 6. The estimated burden of inﬂuenza, in terms of the 200 year cumulative discounte
ith  no vaccination and current practice are included for comparison.ectiveness of the policy predicted to provide the highest expected net beneﬁt.
3.3.4. Direct effects
If only the effects of vaccine protection on those targeted for
immunisation are considered (Table A5), then the estimated ben-
eﬁts of vaccination are signiﬁcantly reduced and estimated costs
increase. The resulting cost-effectiveness frontier (Fig. A4)  would,
however, still result in vaccination of 2–18 year olds with LAIV
being chosen as the optimum strategy, from those included in the
analysis. The vaccine price break even point is reduced to approxi-
mately £100.
4. Discussion
4.1. Indirect protection
This analysis suggests that indirect protection, arising fromdebate over the strength of vaccine induced herd immunity
to inﬂuenza [38], however a recent randomised trial, to assess
d cost and QALYs lost, at increasing annual paediatric vaccination rates. Scenarios
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Table  5
Scenario analysis, exploring the effect of increasing the annual paediatric LAIV uptake rate in children aged 2–18 years. Paediatric vaccination is assumed to occur in addition
to  current practice and to exclusively use LAIV. Cumulative ﬁgures over 200 years.
Scenario QALYs lost (millions) Cost (millions) Incremental
QALYs (millions)
Incremental cost
(millions)
ICER
Current policy 7.73 £18,304
LAIV uptake rate:
10% 5.56 £17,818 2.17 −£486 Cost saving
30%  2.26 £18,040 5.46 −£264 Cost saving
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70% 0.60  £22,511 
90% 0.39  £25,275 
hether vaccinating children and adolescents with inactivated
nﬂuenza vaccine could prevent inﬂuenza in other community
embers [39], has provided direct evidence for this effect.
Indirect protection is expected to result in net cost savings in the
nvaccinated segments of the population particularly in the elderly,
espite pre-existing vaccination coverage of 75%. This may  be the
esult of both a lower vaccine efﬁcacy [16,40,41] and a greater risk
f costly hospitalisation in the elderly. Much of the cost saving in
his age group is therefore the result of averted hospitalisations.
he elderly are also at increased risk of mortality from inﬂuenza,
onsequently, averted infections lead to signiﬁcant gains in QALYs.
The very young are frequently presented to their general prac-
itioner as a result of inﬂuenza, and so also beneﬁt from indirect
rotection, while averted consultations in this age group are pre-
icted to result in a net cost saving to the health service.
While dynamic transmission models have been used previously
o study the impact of paediatric vaccination on the incidence of
nﬂuenza [42,43],  cost-effectiveness analyses have used static anal-
ses that ignore the indirect effects resulting from herd immunity.
hese cost-effectiveness analyses have been reviewed elsewhere
5]. Most estimate that paediatric vaccination is cost saving
3,44,45] or would incur only a modest cost [46,47]. So while there
ould clearly be direct beneﬁts to children, this analysis suggests
hat including indirect protection signiﬁcantly increases the esti-
ated cost-effectiveness of paediatric vaccination. Furthermore,
erd immunity would be expected to protect those at greatest
isk of inﬂuenza related complications, without exposing these risk
roups to the very small risk of vaccine related complications. By
accinating children, an age group thought to play a signiﬁcant role
n inﬂuenza transmission [48,49], these gains would be achieved by
 programme that targets less than 25% of the total population..2. Vaccination coverage
The effective reproductive number of a pathogen (R) is deﬁned
s the number of secondary infections arising from one primary
ig. 7. Relationship between the incremental cost-effectiveness ratio (ICER) and
he annual paediatric LAIV uptake rate in children aged 2–18 years old. Paediatric
accination is assumed to occur in addition to current practice and to exclusively
se  LAIV.6.65 £1669 £251
7.13 £4207 £590
7.33 £6971 £951
infection. If the population is entirely susceptible to infection it is
called the basic reproductive number (R0). The aim of any vaccina-
tion programme should be to reduce R to below 1, resulting in a
decline over time in the number infected. There is therefore a crit-
ical level of effective coverage (the product of uptake and vaccine
efﬁcacy) at which R equals 1. In a randomly mixing population, this
equates to approximately 1 − 1/R0. Once this level of uptake has
been achieved, further increases in uptake will yield diminishing
returns.
In the United States, the CDC recommends inﬂuenza vaccination
for children aged 6 months and older, however, overall vaccination
rates against seasonal inﬂuenza have not exceeded 50% [50]. While
it may  be possible to achieve higher rates of coverage in England
and Wales, increasing coverage beyond 50% may  not be necessary.
Maintaining an uptake rate above the critical threshold may  well
be easier with a vaccine that is not injected but delivered via a nasal
spray, such as LAIV, especially if it could be delivered, at least in part,
via the schools vaccination programme. It is of note that paediatric
vaccination of 2–18 year olds is estimated to remain cost-effective
at annual rates of uptake as low as 10%, at which it may be cost
saving, up to at least 90% uptake.
There is considerable uncertainty surrounding the level of vac-
cine coverage that will in practice be achieved, should a policy of
paediatric inﬂuenza vaccination be implemented in England and
Wales. This will in part be inﬂuenced by the effort invested in reach-
ing out to eligible individuals and by the balance of risk and beneﬁt,
as perceived by parents [51–53]. The fact that there is uncertainty
around the level of coverage is why  the coverage level was sub-
jected to a sensitivity analysis.
4.3. Vaccination setting
This analysis has, conservatively, taken the most expensive
setting for vaccine delivery, that of vaccination by a general prac-
titioner within primary care. Delivery in other settings, such as via
the schools vaccination scheme and within day care centres could
potentially further decrease costs and increase cost-effectiveness,
and would avoid further burdening primary care physicians and
their staff. This is a potential area for further research, as is the
acceptability of immunisation via a nasal spray rather than by
injection.
4.4. Limitations
Those cases of inﬂuenza seen by the health service represent
only a small proportion of those with symptoms and an even
smaller proportion of those infected by the inﬂuenza virus. Esti-
mating the impact of vaccination on the incidence of disease and
the resulting burden on individuals and the health service, requires
a population wide estimate of the incidence of infection. Pop-
ulation wide sero-epidemiological surveys are a source of such
information, however the last time such a study was carried out on
inﬂuenza was  in the 1970s in Tecumseh, in the United States [54]. As
the pattern of population mixing and population densities are likely
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o have changed over the intervening years, models of inﬂuenza
irus transmission would beneﬁt from a more contemporary study.
A further consideration is that a number of different pathogen
nfections can present as an inﬂuenza-like-illness. These include
espiratory syncytial virus, parainﬂuenza, rhinovirus, aden-
virus, Streptococcus pneumoniae, Mycoplasma pneumoniae and
aemophilus inﬂuenzae.  Primary care ILI consultations are rarely
irologically conﬁrmed as being the result of an inﬂuenza virus
nfection. Consequently, the costing of staff time and prescribing in
rimary care may  be an underestimate if those patients presenting
ith inﬂuenza are on average more seriously ill, requiring more
taff time and account for a disproportionate share of prescribed
ntibiotics. Failure to account for such a bias would result in
aediatric vaccination appearing to be less cost-effective than it
ctually is.
The cost of implementing each of the policies considered was
ssumed to be the product of the number vaccinated and the
ost per vaccination. In reality, achieving high uptake rates usu-
lly means accessing difﬁcult to reach groups, which requires a
isproportional investment. The advantage of lower uptake rates
emaining cost-effective may  therefore be greater than has been
stimated.
. ConclusionsOverall, implementing a policy to vaccinate 2–18 year olds with
 live attenuated vaccine, in addition to current practice, is expected
o save 6.65 million quality adjusted life years over a 200 year time
ig. A1. Results of the univariate sensitivity analysis; changes in the ICER produced
y  a 10% variation in key parameters, either side of their base value, see Table 4,
hen vaccinating 2–18 year old children at a coverage of (a) 50% and (b) 80%.31 (2013) 927– 942 935
horizon at a cost per QALY of approximately £251. This illustrates
the importance of considering the population wide impact of vac-
cinating against an infectious disease, rather than just focusing on
the vaccinated population.
While there is appreciable uncertainty in the estimates of
cost-effectiveness, the conclusion that childhood vaccination is
cost-effective would appear to be robust.
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Appendix A.
Model parameters
See Tables A1 and A2 .
Probabilistic sensitivity analysis
See Table A3.
Univariate sensitivity analysis
See Table A4 and Figs. A1–A3 .
Direct effects
See Table A5 and Fig. A4.
CodesSee Table A6.
Fig. A2. Impact on the ICER of vaccinating (a) 50% and (b) 80% of 2–18 year old
children under various ‘what if’ options. See text for details.
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Table  A1
Outline of the parameters used in the deterministic transmission model [6].
Parameter Value Source/comment
Transmission coefﬁcient between age a and a′ (ˇa,a′ ) 3.99 × 10−08 Chosen to give a mean R0 of 1.8 [55]
Mean duration of latency () 2 days Based on volunteer challenge studies [56]
Mean  duration of infectiousness () 2 days Based on volunteer challenge studies [56]
Mean  duration of natural immunity (ωi) Inﬂuenza A: 6 years
Inﬂuenza B: 12 years
The duration of protection is likely to be variable. These values are
consistent with the observed dynamics of inﬂuenza and are consistent
with those used by Vynnycky et al. [42]
Mean  duration of vaccine induced immunity (ωv) Inﬂuenza A: 6 years
Inﬂuenza B: 12 years
Assumed to be equal to natural immunity, unless stated otherwise
Seasonal forcing 1.43 The maximum factor by which R0 differs from the mean [42,57].
Assumed to be sinusoidal
Annual birth rate 621,300/year Number of live births per year [58]
Inﬂuenza independent mortality rate 0 for age <65 years
1/25 years for age
65+ years
Assumed to be zero up to the age of 64. Thereafter, is assumed to be
constant [59]
Population mixing matrix See Ref. [36] The Great Britain ‘All reported contacts’ matrix was used
Table A2
The percentage efﬁcacy [16,17] and uptake of TIV in England and Wales assumed by the model (Health Protection Agency data, www.HPA.org.uk, accessed 22 January 2010).
Age groups in model % efﬁcacy % uptake in total population
0 to <1 60% 0.1%
1  to <2 60% 0.1%
2  to <5 60% 1.4%
5  to <11 60% 1.4%
11  to <19 60% 1.4%
19  to <50 75% 5.6%
50  to <65 75% 5.6%
65+  50% 73.5%
Table A3
Parameters included in the economic model with details of the sampling distributions used in the probabilistic sensitivity analysis.
Name Age group Deterministic Probabilistic sensitivity analysis only Source
Standard error Distribution alpha beta
Mean annual number of hospital
admissions resulting from
inﬂuenza A
0–11 mo  909 155 gamma  34.57 26.28
See Ref. [1]
12–23 mo  895 152 gamma  34.57 25.89
24–59 mo  2396 408 gamma  34.57 69.30
5–10  yr 2 1 gamma  4.00 0.50
11–18 yr 184 51 gamma 12.91 14.22
19–49 yr 1640 985 gamma  2.77 591.00
50–64 yr 1676 2281 gamma  0.54 3103.14
65+  yr 11,300 1276 gamma  78.49 143.98
All  ages 19,000 2551 gamma  55.47 342.51
Mean  annual number of hospital
admissions resulting from
inﬂuenza B
0–11 mo  2 1 gamma  4.00 0.50
See Ref. [1]
12–23 mo  2 1 gamma  4.00 0.50
24–59 mo  2 1 gamma  4.00 0.50
5–10  yr 2 1 gamma  4.00 0.50
11–18 yr 2 1 gamma  4.00 0.50
19–49 yr 337 375 gamma  0.81 417.65
50–64 yr 763 849 gamma  0.81 945.42
65+  yr 2400 1276 gamma  3.54 677.89
All  ages 3500 2551 gamma  1.88 1859.34
Mean  annual number of deaths
resulting from inﬂuenza A
0–11 mo  0.7 0.3 gamma  4.69 0.14
See Ref. [1]
12–23 mo  0.7 0.3 gamma  4.69 0.14
24–59 mo  2 0.8 gamma  4.69 0.38
5–10  yr 7 3 gamma  4.69 1.41
11–18 yr 16 4 gamma  19.84 0.79
19–49 yr 288 25 gamma  131.74 2.18
50–64 yr 524 35 gamma  225.00 2.33
65+  yr 12,800 800 gamma  256.00 50.00
All  ages 13,650 900 gamma  230.03 59.34
Mean  annual number of deaths
resulting from inﬂuenza B
0–11 mo  0.2 0.1 gamma  10.67 0.02
See Ref. [1]
12–23 mo  0.2 0.1 gamma  10.67 0.02
24–59 mo  0.6 0.2 gamma  10.67 0.06
5–10  yr 3 0.9 gamma  10.67 0.26
11–18 yr 3 0.8 gamma  13.13 0.22
19–49 yr 29 6 gamma  26.00 1.12
50–64 yr 47 8 gamma  33.58 1.40
65+  yr 1400 179 gamma  61.47 22.78
All  ages 1450 204 gamma  50.48 28.72
R.J. Pitman et al. / Vaccine 31 (2013) 927– 942 937
Table  A3 (Continued)
Name Age group Deterministic Probabilistic sensitivity analysis only Source
Standard error Distribution alpha beta
Mean cost of inﬂuenza related
hospitalisation
0–11 mo £1606 £449 gamma  12.79 125.60 National schedule of reference
costs 2007–08 for NHS trusts,
non-elective inpatient (long stay)
HRG  data [13]/Hospital Episode
Statistics 2005/06 [10]
12–23  mo  £1606 £449 gamma  12.79 125.60
24–59 mo  £1606 £449 gamma  12.79 125.60
5–10 yr £1606 £449 gamma 12.79 125.60
11–18 yr £1634 £457 gamma  12.79 127.78
19–49 yr £1662 £465 gamma  12.79 129.96
50–64 yr £1983 £555 gamma  12.79 155.08
65+ yr £5354 £1497 gamma  12.79 418.65
All  ages £2123 £594 gamma  12.79 166.00
QALY decrement for an inﬂuenza episode 0.02 Beta 110.94 2476.02 See Ref. [11]
Mean GP costs of inﬂuenza related
episode
0–11 mo £88
Personal and Social Services
Research Unit [7]/General Practice
Research Database
12–23 mo  £88
24–59 mo  £65
5–10 yr £54
11–18 yr £66
19–49 yr £85
50–64 yr £101
65+ yr £100
All ages £80
Mean cost of vaccinating with TIV 0–11 mo £38.60
British National Formulary (release
57) [12], see text
12–23 mo  £38.60
24–59 mo  £38.60
5–10 yr £38.60
11–18 yr £38.60
19–49 yr £38.60
50–64 yr £38.60
65+ yr £38.60
All ages £38.60
Mean cost of vaccinating with LAIV 0–11 mo £38.60
Assumed parity with TIV, see text
12–23 mo  £38.60
24–59 mo  £38.60
5–10 yr £38.60
11–18 yr £38.60
19–49 yr £38.60
50–64 yr £38.60
65+ yr £38.60
All ages £38.60
Simulated annual incident cases,
averaged over 10 years Inﬂuenza A
0–11 mo 125,991
Estimated under current practice,
see text
12–23 mo  121,034
24–59 mo  299,258
5–10 yr 822,162
11–18 yr 566,111
19–49 yr 1,861,060
50–64 yr 779,582
65+ yr 143,975
All ages 4,719,174
Simulated annual incident cases,
averaged over 10 years Inﬂuenza B
0–11 mo 25,028
Estimated under current practice,
see text
12–23 mo  24,763
24–59 mo  68,490
5–10 yr 306,119
11–18 yr 227,453
19–49 yr 592,841
50–64 yr 216,508
65+ yr 31,308
All ages 1,492,509
Table A4
Parameter values varied in the univariate sensitivity analysis and the ranges used (base value ± 10%).
Base value Units Range
Basic reproductive number 1.8 – 1.62–1.98
Seasonality 1.43 – 1.29–1.57
Duration of immunity inﬂuenza A 6 years 5.40–6.60
Duration of immunity inﬂuenza B 12 years 10.80–13.20
LAIV  price 5.81 £ 5.23–6.39
Seeding 10 – 9–11
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Fig. A3. Extreme value analysis: ICERs (LAIV at 50% uptake in 2–18 year olds vs current practice) calculated using systematic combinations of low, baseline, and high
parameter values, see text for details.
Table A5
Incremental cost-effectiveness analysis of the direct effects of implementing a programme of paediatric inﬂuenza vaccination in children aged 2–4, 2–10 or 2–18 years old,
exclusively using either a live attenuated inﬂuenza vaccine (LAIV) or a trivalent inﬂuenza vaccine (TIV), in addition to current practice. An annual paediatric vaccine uptake
rate  of 50% is assumed.
Policy option QALYs lost (millions) Cost (millions) Incremental QALYs (millions) Incremental cost (millions) ICER
No vaccination −1.52 £903
Current policy −1.28 £928 0.24 £25 £101
Current policy + TIV in 2–4 year olds −0.86 £2161 0.42 £1233 Dominated
Current policy + LAIV in 2–4 year olds −0.77 £2108 0.51 £1179 £2318
Current policy + TIV in 2–10 year olds −0.40 £4933 0.37 £2826 Dominated
Current policy + LAIV in 2–10 year olds −0.31 £4881 0.46 £2774 £5991
Current policy + TIV in 2–18 year olds −0.11 £7434 0.20 £2552 Dominated
Current policy + LAIV in 2–18 year olds −0.06 £7400 0.25 £2519 £9995
Table A6
General Practice Research Database standard code list for inﬂuenza-like illness.
GPRD medical code Term type Read/OXMIS code Read/OXMIS term
202167 OXMIS 472 A Inﬂuenzal bronchitis
206777 READ F030800 Encephalitis due to inﬂuenza-speciﬁc virus not identiﬁed
207166 READ H060w00 Acute viral bronchitis unspeciﬁed
207185  READ H2. . .00 Pneumonia and inﬂuenza
207185 READ H2. . .00 Pneumonia and inﬂuenza
207186 READ H22z.00 Bacterial pneumonia NOS
207189 READ H270z00 Inﬂuenza with pneumonia NOS
207190 READ H271000 Inﬂuenza with laryngitis
207191 READ H271100 Inﬂuenza with pharyngitis
207192 READ H27y.00 Inﬂuenza with other manifestations
207193 READ H300.00 Tracheobronchitis NOS
211144 OXMIS 465 TP Tracheopharyngitis
211146 OXMIS 473 E Inﬂuenzal enteritis
216108 READ H054.00 Recurrent upper respiratory tract infection
216110  READ H060500 Acute tracheobronchitis
216112 READ H060z00 Acute bronchitis NOS
216113 READ H06z200 Recurrent chest infection
216131 READ H20..00 Viral pneumonia
216134 READ H20z.00 Viral pneumonia NOS
216135 READ H21..00 Lobar (pneumococcal) pneumonia
216141 READ H25..11 Chest infection – unspeciﬁed bronchopneumonia
216173 READ Hyu0.00 [X]Acute upper respiratory infections
216175 READ Hyu1.00 [X]Other acute lower respiratory infections
220236 OXMIS 472 L Laryngitis With Inﬂuenza
220743 OXMIS 7889EL Chill on lung
222254 READ 663a.00 Oral steroids used since last appointment
225105 READ G520300 Acute myocarditis – inﬂuenzal
225218 READ H06z112 Acute lower respiratory tract infection
225219 READ H0y..00 Other speciﬁed acute respiratory infections
225238 READ H24yz00 Pneumonia with other infectious diseases EC NOS
225239 READ H27z.12 Inﬂuenza like illness
225240  READ H301.00 Laryngotracheobronchitis
225241 READ H30z.00 Bronchitis NOS
225280 READ Hyu0800 [X]Other viral pneumonia
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Table  A6 (Continued)
GPRD medical code Term type Read/OXMIS code Read/OXMIS term
229330 OXMIS 471 Pneumonia inﬂuenza
229332 OXMIS 490 T Tracheobronchitis
230294 READ 12D1.11 FH: Bronchitis
234341 READ H061z00 Acute bronchiolitis NOS
234367 READ H24..11 Chest infection with infectious disease EC
234370 READ H270.00 Inﬂuenza with pneumonia
234371 READ H270000 Inﬂuenza with bronchopneumonia
234372 READ H271z00 Inﬂuenza with respiratory manifestations NOS
234373 READ H27yz00 Inﬂuenza with other manifestations NOS
234394 READ H56y100 Interstitial pneumonia
234402 READ H5yy.11 Respiratory infection NOS
234407 READ Hyu0700 [X]Inﬂuenza + other manifestations, virus not identiﬁed
239395 READ 14B3.11 H/O: bronchitis
242993 READ F030A00 Encephalitis due to inﬂuenza-virus identiﬁed
243347 READ H051.00 Acute upper respiratory tract infection
243348 READ H05z.11 Upper respiratory tract infection NOS
243349 READ H06..00 Acute bronchitis and bronchiolitis
243353 READ H062.00 Acute lower respiratory tract infection
243354 READ H06z111 Respiratory tract infection
243382 READ H22y.00 Pneumonia due to other speciﬁed bacteria
243384 READ H24..00 Pneumonia with infectious diseases EC
243385 READ H25..00 Bronchopneumonia due to unspeciﬁed organism
243386 READ H27z.00 Inﬂuenza NOS
243387 READ H2z..00 Pneumonia or inﬂuenza NOS
243387 READ H2z..00 Pneumonia or inﬂuenza NOS
243389 READ H30..00 Bronchitis unspeciﬁed
247427 OXMIS 464 LT Laryngotracheitis
248501 READ 12D1.00 FH: Bronchitis/COAD
252485 READ H061.00 Acute bronchiolitis
252486 READ H0z..00 Acute respiratory infection NOS
252501 READ H23..11 Chest infection – pneumonia organism OS
252506 READ H24z.00 Pneumonia with infectious diseases EC NOS
252507 READ H26..00 Pneumonia due to unspeciﬁed organism
252509 READ H261.00 Basal pneumonia due to unspeciﬁed organism
252510 READ H27..00 Inﬂuenza
252511 READ H27z.11 Flu like illness
252512 READ H2y..00 Other speciﬁed pneumonia or inﬂuenza
252524 READ H3y0.00 Chronic obstruct pulmonary disease with acute lower respiratory infection
252524 READ H3y0.00 Chronic obstruct pulmonary disease with acute lower respiratory infection
252538 READ H530300 Abscess of lung with pneumonia
256644 OXMIS 465 RC Upper respiratory infection recurrent
256648 OXMIS 493 A Bronchitis allergic
258758 READ 663Y.00 Steroid dose inhaled daily
258759 READ 663g100 Using inhaled steroids – normal dose
261710 READ H060.11 Acute wheezy bronchitis
261711 READ H060300 Acute purulent bronchitis
261712 READ H060400 Acute croupous bronchitis
261715 READ H06z100 Lower respiratory tract infection
261740 READ H20..11 Chest infection – viral pneumonia
261742 READ H271.00 Inﬂuenza with other respiratory manifestation
261743 READ H310000 Chronic catarrhal bronchitis
261744 READ H312100 Emphysematous bronchitis
261780 READ Hyu0A00 [X]Other bacterial pneumonia
263839 READ SP13200 Post operative chest infection
267998 READ 663F.00 Oral steroids started
270992 READ H0. . .00 Acute respiratory infections
271004 READ H05..00 Other acute upper respiratory infections
271005 READ H05y.00 Other upper respiratory infections of multiple sites
271006 READ H05z.12 Viral upper respiratory tract infection NOS
271030 READ H22..11 Chest infection – other bacterial pneumonia
271033 READ H23..00 Pneumonia due to other speciﬁed organisms
271034 READ H23z.00 Pneumonia due to speciﬁed organism NOS
275002 OXMIS 464 P Tracheitis purulent
275003 OXMIS 465 B Upper respiratory infection acute viral
275004 OXMIS 465 LP Pharyngolaryngitis
275007 OXMIS 472 H Inﬂuenza haemorrhagic
275010 OXMIS 483 AP Pneumonia primary atypical
276135 READ 14B2.00 H/O: pneumonia
277046 READ 663g.00 Inhaled steroids use
280056 READ H06z011 Chest infection
280074 READ H20y.00 Viral pneumonia NEC
280078 READ H24y.00 Pneumonia with other infectious diseases EC
280080 READ H27y100 Inﬂuenza with gastrointestinal tract involvement
280082 READ H30..11 Chest infection – unspeciﬁed bronchitis
280083 READ H30..12 Recurrent wheezy bronchitis
280084 READ H302.00 Wheezy bronchitis
280087 READ H312000 Chronic asthmatic bronchitis
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Table  A6 (Continued)
GPRD medical code Term type Read/OXMIS code Read/OXMIS term
284113 OXMIS 472 B Tracheitis inﬂuenza
286208 READ 663g200 Using inhaled steroids – high dose
289163 READ H05z.00 Upper respiratory infection NOS
289164 READ H060.00 Acute bronchitis
289166 READ H060v00 Subacute bronchitis unspeciﬁed
289167 READ H061600 Acute bronchiolitis due to other speciﬁed organisms
289192 READ H26..11 Chest infection – pneumonia due to unspeciﬁed organism
289193 READ H270.11 Chest infection – inﬂuenza with pneumonia
289194 READ H270100 Inﬂuenza with pneumonia, inﬂuenza virus identiﬁed
289194 READ H270100 Inﬂuenza with pneumonia, inﬂuenza virus identiﬁed
289197 READ H333.00 Acute exacerbation of asthma
289218 READ H540000 Hypostatic pneumonia
289231 READ Hyu0600 [X]Inﬂuenza + other respiratory manifestations, virus not identiﬁed
293231 OXMIS 466 BC Bronchitis subacute
295374 READ 663g300 Increases inhaled steroids appropriately
298436 READ H060x00 Acute bacterial bronchitis unspeciﬁed
298437 READ H061200 Acute bronchiolitis with bronchospasm
298437 READ H061200 Acute bronchiolitis with bronchospasm
298440 READ H06z.00 Acute bronchitis or bronchiolitis NOS
298441 READ H06z000 Chest infection NOS
298466 READ H22..00 Other bacterial pneumonia
298473 READ H260.00 Lobar pneumonia due to unspeciﬁed organism
298474  READ H27y000 Inﬂuenza with encephalopathy
298475 READ H28..00 Atypical pneumonia
298510 READ Hyu0500 [X]Inﬂuenza + other manifestations, inﬂuenza virus identiﬁed
303927 OXMIS 460 C Inﬂuenza-like illness
303930 OXMIS 460 DC Coryza
303943 OXMIS 464 B Laryngitis
303944 OXMIS 464 D Tracheitis
303945 OXMIS 464 E Croup
303946 OXMIS 464 LA Laryngotracheitis acute
303947 OXMIS 465 URTI (upper respiratory tract infection)
303948 OXMIS 465 A Upper respiratory infection acute
303949 OXMIS 465 AA URI (upper respiratory infection)
303950 OXMIS 466 A Bronchiolitis
303951 OXMIS 466 B Bronchiolitis acute
303952 OXMIS 466 C Bronchitis acute
303953 OXMIS 466 CR Croup bronchial
303954 OXMIS 466 V Viral bronchitis
303955 OXMIS 470 Inﬂuenza
303956 OXMIS 470 F Flu
303958 OXMIS 480 Virus pneumonia
303959 OXMIS 481 B Lobar pneumonia
303960 OXMIS 481 BA Pneumonia basal
303961 OXMIS 483 AT Pneumonia atypical
303963 OXMIS 485 Bronchopneumonia
303964 OXMIS 486 Pneumonia
303966 OXMIS 490 Bronchitis
303968 OXMIS 490 LT Laryngotracheobronchitis
303969 OXMIS 490 WH Wheezy bronchitis
303971 OXMIS 491 AC Bronchitis acute on chronic
303980 OXMIS 493 C Croup asthmatic
303987 OXMIS 493 KA Exacerbation of asthma
303988 OXMIS 493 KB Asthma exacerbation
304068 OXMIS 5199D RTI (respiratory tract infection)
304069 OXMIS 5199E Infection chest
306516 OXMIS 460 E Coryza recurrent
306523 OXMIS 464 C Tracheitis acute
306525 OXMIS 466 D Bronchitis purulent
306528 OXMIS 490 CT Catarrhal bronchitis
306529 OXMIS 491 R Bronchitis recurrent
306536 OXMIS 493 BD Asthma and bronchitis
306593 OXMIS 5199RN Recurrent chest infection
308502 READ 16L..00 Inﬂuenza-like symptoms
308788 READ h060.00 Acute bronchitis
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Fig. A4. Cost-effectiveness acceptability frontier, over a range of cost-effectiveness
thresholds and including only those costs and QALYs accrued in the paediatric
population targeted for vaccination, estimating the probability of the optimum
vaccination policy being cost-effective. An annual paediatric uptake rate of 50% is
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